Sandra Horning

Today's approval of Rozlytrek represents a new chapter in personalized healthcare, applying advanced diagnostics to deliver precision medicines.

These are the first positive Phase III survival results for any immunotherapy-based combination in the initial treatment of extensive-stage small cell lung cancer.